Congress mandates fast-track drug access for patients denied by insurers
H.R. 5509 — Safe Step Act · Filed by Rick Allen (R-GA) · 169 cosponsors · Introduced Sep 19, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires health insurance plans to create a clear, fast process for patients and doctors to request exceptions to 'step therapy' protocols—rules that force patients to try cheaper drugs first before insurers will cover the prescribed medication. If a patient meets one of six defined circumstances (prior drugs failed, delay would cause harm, contraindication, loss of function, or prior approval elsewhere), the plan must approve the exception within 72 hours (or 24 hours in emergencies) and cover the requested drug for at least one year. Plans must report annually to the Department of Labor on exception requests, approvals, and denials.
Why we flagged it
The bill's operative mechanism is a procedural right—it mandates a transparent exception process for step therapy denials. It does not ban step therapy itself, but constrains insurer discretion and creates enforceable timelines and criteria for exceptions, shifting leverage toward patients and prescribers.
What the text implies
- Reporting requirements may expose patterns in step therapy denials by medical specialty and condition, creating public data that could inform future regulation or litigation against insurers.
- The 'other circumstances' catch-all in subsection (b)(6) delegates authority to the Secretary of Labor to expand exception grounds post-enactment, potentially broadening patient access beyond the six enumerated categories.
- Pharmacy benefit managers (PBMs) are named as entities whose contracts cannot prevent plans from obtaining data needed for compliance, potentially weakening PBM opacity and control over formulary decisions.
- One-year minimum coverage duration for approved exceptions may increase insurer costs if patients remain on higher-cost drugs longer than step therapy was designed to prevent.
- The bill applies to all group health plans and health insurance coverage, including self-insured plans, creating uniform federal baseline that may preempt state-level step therapy protections.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Patients and doctors gain a transparent, time-bound right to challenge step therapy denials, reducing delays in accessing prescribed medications and preventing harm from forced switches to ineffective drugs. Insurers retain step therapy as a cost-control tool but lose the ability to deny exceptions arbitrarily or without clear process, shifting power from plan administrators to patients and prescribers.
Who stands to gain
- pharmaceutical manufacturers (brand-name and specialty drugs)
- patients requiring non-preferred medications
- prescribers (reduced administrative burden from step therapy denials)
Named in the bill
Employee Retirement Income Security Act of 1974 (ERISA), Department of Labor (DOL), group health plans, health insurance issuers, pharmacy benefit managers (PBMs), third-party administrators, prescribers, participants and beneficiaries
Where it stands
169 cosponsors: 113 Democrats, 56 Republicans.
- Sep 19, 2025 — Introduced · Congress.gov: “Introduced in House”
- Sep 19, 2025 — Referred to House Committee on Education and Workforce · Congress.gov: “Referred to the House Committee on Education and Workforce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
34 lobbying clients named this bill on 44 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $20,408,310 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 98% of bills with at least one filing.
Rick Allen, the sponsor, reported $565,250 in PAC receipts in the 2026 cycle. $13,500 of that came from 3 PACs tied to these lobbying clients.
- American Cancer Society Cancer Action Network Inc — $3,620,000 on 2 filings
- Bristol-myers Squibb Company — $3,160,000 on 1 filing
- Pfizer Inc. — $1,720,000 on 1 filing
- Astrazeneca Pharmaceuticals Lp — $1,680,000 on 1 filing
- Johnson & Johnson Services Inc — $1,440,000 on 1 filing
Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (12,941 characters) on Aug 14, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 21, 2026 · page rendered 2026-10-20.
“Congress mandates fast-track drug access for patients denied by insurers” QuorumCivic. https://share.quorumcivic.app/bill/119/hr5509 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.